Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
- 20 October 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (11)
- https://doi.org/10.1128/aac.01521-20
Abstract
Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir’s metabolite (GS-441524) and sulfobutylether β-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).This publication has 9 references indexed in Scilit:
- Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19Journal of Antimicrobial Chemotherapy, 2020
- Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysisThe Lancet, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus diseaseJournal of Antimicrobial Chemotherapy, 2020
- Care for Critically Ill Patients With COVID-19JAMA, 2020
- Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidenceTravel Medicine and Infectious Disease, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal ImpairmentThe Journal of Clinical Pharmacology, 2018
- Pharmacokinetics of sulfobutylether- -cyclodextrin (SBECD) in subjects on hemodialysisNephrology Dialysis Transplantation, 2011